
Gillian Vandekerkhove

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/289903/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. European Urology Oncology, 2022, 5, 677-686.	5.4	6
2	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research, 2021, 27, 1650-1662.	7.0	52
3	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research, 2021, 27, 4610-4623.	7.0	41
4	Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Annals of Oncology, 2021, 32, 896-905.	1.2	39
5	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. Urology Case Reports, 2021, 39, 101762.	0.3	0
6	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	12.8	85
7	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1114-1125.	7.0	57
8	Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. Npj Genomic Medicine, 2020, 5, 12.	3.8	9
9	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	1.9	47
10	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 826-836.	1.6	33
11	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 2019, 75, 707-711.	1.9	89
12	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	1.9	131
13	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	9.4	376
14	Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology, 2018, 1, 122.	4.4	21
15	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	1.9	179
16	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	7.0	121